162 related articles for article (PubMed ID: 19920916)
1. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
Lewis KA; Eugster EA
Drug Des Devel Ther; 2009 Sep; 3():1-5. PubMed ID: 19920916
[TBL] [Abstract][Full Text] [Related]
2. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
3. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
6. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
Ray LA; Eckert GJ; Eugster EA
J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262
[TBL] [Abstract][Full Text] [Related]
7. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
Silverman LA; Han X; Huang H; Near AM; Hu Y
J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
[TBL] [Abstract][Full Text] [Related]
9. Histrelin for central precocious puberty-a single surgeon experience.
Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
[TBL] [Abstract][Full Text] [Related]
10. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Lewis KA; Goldyn AK; West KW; Eugster EA
J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
[TBL] [Abstract][Full Text] [Related]
11. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.
Rahhal S; Clarke WL; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Eugster EA
Int J Pediatr Endocrinol; 2009; 2009():812517. PubMed ID: 19956699
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
Lerman L; Yackobovitch-Gavan M; Phillip M; Shalitin S
Pediatr Res; 2024 Mar; 95(4):1051-1059. PubMed ID: 37935883
[TBL] [Abstract][Full Text] [Related]
13. Experience with the Histrelin Implant in Pediatric Patients.
Eugster EA
Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.
Klein KO; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Med Econ; 2020 Apr; 23(4):407-414. PubMed ID: 31766907
[No Abstract] [Full Text] [Related]
16. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty.
Kim EY
Korean J Pediatr; 2015 Jan; 58(1):1-7. PubMed ID: 25729392
[TBL] [Abstract][Full Text] [Related]
17. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
Tao Y; Si C; Li H; Han J; Hou H; Yang M
Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
[TBL] [Abstract][Full Text] [Related]
18. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
[TBL] [Abstract][Full Text] [Related]
19. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy.
Neely EK; Silverman LA; Geffner ME; Danoff TM; Gould E; Thornton PS
Int J Pediatr Endocrinol; 2013 Dec; 2013(1):20. PubMed ID: 24295437
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.
Popovic J; Geffner ME; Rogol AD; Silverman LA; Kaplowitz PB; Mauras N; Zeitler P; Eugster EA; Klein KO
Front Pediatr; 2022; 10():968485. PubMed ID: 36268040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
